Cisatracurium-besilate
- PDF / 169,367 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 87 Downloads / 140 Views
1 S
Cisatracurium-besilate Apnoea: case report
In a retrospective study of 168 patients who were undergone laparoscopic pyloromyotomy between January 2017 and July 2015, an infant [sex and exact age not stated] was described, who developed apnoea following induction of anaesthesia with cisatracurium-besilate. The infant, who had hypertrophic pyloric stenosis, was planned to undergo laparoscopic pyloromyotomy. Subsequently, the infant was rehydrated and received electrolyte supplementation. Thereafter, the infant received cisatracurium-besilate [cisatracurium] for induction of anaesthesia [route and dosage not stated], and for maintenance of anesthesia, the patient received sevoflurane. However, following the surgery, the patient was admitted to pediatric ICU, due to apnoea with desaturation. The patient required oxygen supplementation via mask ventilation [outcome not stated]. It was concluded that the apnoea was associated with neuromuscular blocking drug cisatracurium besilate. Swenker D, et al. Neuromuscular Blocking Agents and Rapid Sequence Induction for Laparoscopic Pyloromyotomy: Impact on Time to Extubation and Perioperative Complications. European Journal of Pediatric Surgery 30: 440-446, No. 5, 2020. Available from: URL: http://doi.org/10.1055/s-0039-1692656
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803520844
Reactions 12 Dec 2020 No. 1834
Data Loading...